Zenas BioPharma, Inc.
ZBIO
$32.36
-$0.69-2.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -93.33% | -100.00% | 100.00% | -- | -70.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.33% | -100.00% | 100.00% | -- | -70.00% |
| Cost of Revenue | 32.90% | 27.86% | 20.79% | 46.29% | 86.30% |
| Gross Profit | -45.90% | -41.92% | -17.84% | -32.70% | -302.05% |
| SG&A Expenses | 41.31% | 55.30% | 79.24% | 117.26% | 115.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.69% | 33.27% | 31.08% | 58.37% | 91.76% |
| Operating Income | -44.84% | -44.79% | -28.98% | -47.09% | -235.08% |
| Income Before Tax | -173.91% | -161.50% | -141.33% | -47.40% | -224.60% |
| Income Tax Expenses | -9.84% | -43.75% | -118.41% | -18.94% | -18.94% |
| Earnings from Continuing Operations | -173.65% | -161.21% | -140.62% | -47.24% | -223.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.65% | -161.21% | -140.62% | -47.24% | -223.26% |
| EBIT | -44.84% | -44.79% | -28.98% | -47.09% | -235.08% |
| EBITDA | -44.91% | -44.87% | -29.06% | -47.18% | -235.63% |
| EPS Basic | -7.93% | 72.97% | 83.86% | 92.82% | 85.05% |
| Normalized Basic EPS | 37.01% | 83.40% | 90.60% | 92.98% | 75.92% |
| EPS Diluted | -7.93% | 72.97% | 83.86% | 92.82% | 85.17% |
| Normalized Diluted EPS | 37.01% | 83.40% | 90.60% | 92.98% | 78.64% |
| Average Basic Shares Outstanding | 60.47% | 107.15% | 239.00% | 1,257.20% | 2,049.66% |
| Average Diluted Shares Outstanding | 60.47% | 107.15% | 239.00% | 1,257.20% | 1,931.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |